Based on all these previous data, we hypothesized that the impact of CD34- and αSMA-positive cancer-associated fibroblasts (CAFs) may be distinct for each subtype and may be accurately enhanced by using DIA associated with immunohistochemistry interpretation. This evidence concerns the gene CD34 and cancer.